Amphastar Pharmaceuticals, Inc.
AMPH· Nasdaq
AMPHAmphastar Pharmaceuticals, Inc.
Filed Mar 11, 2022 · 10-K · 70 days after period end · 0001297184-22-000007
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $120.89M | $95.92M | $83.38M | $89.69M |
| Net Income | $19.76M | -$6.27M | -$1.03M | $1.87M |
| EPS Diluted | — | — | -$0.02 | $0.04 |
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2021 · filed Mar 11, 2022 · 70 d after period end
